{
    "clinical_study": {
        "@rank": "9865", 
        "acronym": "pop", 
        "arm_group": {
            "arm_group_label": "Liuwei Dihuang Pills", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This study use RT-PCR and Western Blot technique to detect the expression of CLCF1 mRNA and\n      protein in POP Kidney Yin deficiency group and healthy group to verify the relevance between\n      CLCF1 and POP the kidney Yin deficiency syndrome.Through siRNA and overexpression,observe\n      the mRNA and protein 's expression of CBP\u3001JAK1\u3001STAT4 and the protein phosphorylation of\n      JAK1\u3001STAT4 in JAK-STAT signal to reveal the CLCF1 regulate the CBP's mechanism.Use the\n      Liuwei Dihuang Pills to detect the effect of treatment ,compare use or not the Liuwei\n      Dihuang Pills to detect the mRNA and protein 's expression of CLCF1\u3001CBP etc.Aim to clarify\n      the POP kidney Yin deficiency molecular mechanism."
        }, 
        "brief_title": "Molecular Mechanism of POP Kidney Yin Deficiency Syndrome From the Interventional Effects of CLCF1", 
        "condition": "Postmenopausal Osteoporosis", 
        "condition_browse": {
            "mesh_term": [
                "Osteoporosis", 
                "Osteoporosis, Postmenopausal", 
                "Yin Deficiency"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  The Participants who volunteer to be test subjects, and can accept experimental\n             drugs, and promise to finish the course should sign the informed consent.\n\n          -  Female ages 45 to 75 had gone through natural menopause before two years\n\n          -  In accordance with the western medicine diagnostic criteria of osteoporosis and\n             belong to kidney Yin deficiency syndrome differentiation of traditional Chinese\n             medicine certificate;\n\n          -  In accordance with the western medicine diagnostic criteria;\n\n          -  In accordance with TCM diagnostic methods; .If any of the above answers are no, The\n             subjects couldn't  in the study.\n\n        Exclusion Criteria:\n\n          -  Do not accord with standard of the western medicine diagnosis and TCM diagnostic\n             methods\n\n          -  Age: <44 and > 76 years old;\n\n          -  With hyperparathyroidism, osteomalacia, rheumatoid arthritis, multiple myeloma and\n             other serious complications such as secondary osteoporosis; Late or deformity,\n             disability, loss of labor;\n\n          -  With cardiovascular, cerebrovascular, liver, kidney and hematopoietic system and\n             other serious primary diseases;\n\n          -  Psychosis or alzheimer's patients;\n\n          -  Nearly three months, the use of hormone replacement therapy (HRT) and taking\n             calcitonin, nearly six months has used double phosphonic acid salt for 15 days, etc.;\n\n          -  This medicine allergic constitution or composition of known to have allergies;\n\n          -  In a critical condition, It's difficult to make exact evaluators to efficacy and\n             safety of the new drugs;"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "75 Years", 
            "minimum_age": "45 Years"
        }, 
        "enrollment": {
            "#text": "25", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01834105", 
            "org_study_id": "81173280"
        }, 
        "intervention": {
            "arm_group_label": "Liuwei Dihuang Pills", 
            "intervention_name": "Liuwei Dihuang Pills", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Postmenopausal osteoporosis; Kidney Yin deficiency syndrome; Liuwei dihuang pill; CLCF1; JAK - STAT signal pathway", 
        "lastchanged_date": "April 17, 2013", 
        "location": {
            "contact": {
                "email": "yjykyb@163.com", 
                "last_name": "xie bin ying, Bachelor", 
                "phone": "86-0591-83570943"
            }, 
            "facility": {
                "address": {
                    "city": "Fu Zhou", 
                    "country": "China", 
                    "state": "Fujian", 
                    "zip": "3530003"
                }, 
                "name": "Fujian Institute of Trational Chiness Medicine"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "Study on the Molecular Mechanism of Postmenopausal Osteoporosis With Kidney Yin Deficiency Syndrome From CLCF1 Interventing on JAK-STAT Signaling Pathways", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "osteoporosis treatment within six months of study enrollment", 
            "safety_issue": "Yes", 
            "time_frame": "Liuwei Dihuang Pills therapy (up to six months)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01834105"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Fujian Institute Of Trational Chinese Medicine", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Fujian Institute Of Trational Chinese Medicine", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}